Compare STRIDES PHARMA SCIENCE with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs PROCTER & GAMBLE HEALTH - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE PROCTER & GAMBLE HEALTH STRIDES PHARMA SCIENCE/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 14.8 55.4 26.7% View Chart
P/BV x 0.9 5.0 17.4% View Chart
Dividend Yield % 0.6 9.5 5.9%  

Financials

 STRIDES PHARMA SCIENCE   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
STRIDES PHARMA SCIENCE/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1,1473,549 32.3%   
Low Rs6421,301 49.3%   
Sales per share (Unadj.) Rs317.2511.4 62.0%  
Earnings per share (Unadj.) Rs7.861.3 12.8%  
Cash flow per share (Unadj.) Rs25.174.0 33.9%  
Dividends per share (Unadj.) Rs2.00440.00 0.5%  
Dividend yield (eoy) %0.218.1 1.2%  
Book value per share (Unadj.) Rs274.3927.8 29.6%  
Shares outstanding (eoy) m89.5016.60 539.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.7 59.5%   
Avg P/E ratio x114.039.6 288.2%  
P/CF ratio (eoy) x35.732.8 109.0%  
Price / Book Value ratio x3.32.6 124.8%  
Dividend payout %25.5717.9 3.6%   
Avg Mkt Cap Rs m80,05840,257 198.9%   
No. of employees `0002.51.1 221.1%   
Total wages/salary Rs m4,3411,313 330.7%   
Avg. sales/employee Rs Th11,325.87,486.7 151.3%   
Avg. wages/employee Rs Th1,731.41,157.6 149.6%   
Avg. net profit/employee Rs Th280.1897.2 31.2%   
INCOME DATA
Net Sales Rs m28,3948,490 334.4%  
Other income Rs m941244 385.6%   
Total revenues Rs m29,3348,734 335.9%   
Gross profit Rs m3,9651,482 267.6%  
Depreciation Rs m1,540211 729.4%   
Interest Rs m1,9620-   
Profit before tax Rs m1,4031,514 92.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-43666 -664.3%   
Tax Rs m97563 17.3%   
Profit after tax Rs m7021,017 69.0%  
Gross profit margin %14.017.5 80.0%  
Effective tax rate %6.937.1 18.7%   
Net profit margin %2.512.0 20.6%  
BALANCE SHEET DATA
Current assets Rs m24,83615,343 161.9%   
Current liabilities Rs m18,9931,960 968.9%   
Net working cap to sales %20.6157.6 13.1%  
Current ratio x1.37.8 16.7%  
Inventory Days Days7149 145.6%  
Debtors Days Days11328 398.6%  
Net fixed assets Rs m34,2891,209 2,835.4%   
Share capital Rs m895166 539.2%   
"Free" reserves Rs m23,65115,235 155.2%   
Net worth Rs m24,54615,401 159.4%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43717,595 371.9%  
Interest coverage x1.7NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 89.9%   
Return on assets %4.15.8 70.4%  
Return on equity %2.96.6 43.3%  
Return on capital %6.910.3 67.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6971,636 959.3%   
Fx outflow Rs m7354,368 16.8%   
Net fx Rs m14,962-2,732 -547.7%   
CASH FLOW
From Operations Rs m1,871-1,304 -143.5%  
From Investments Rs m5,82612,697 45.9%  
From Financial Activity Rs m-10,157-301 3,380.0%  
Net Cashflow Rs m-2,61511,093 -23.6%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 37.8 18.2 207.7%  
FIIs % 8.6 1.0 860.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 29.1 89.0%  
Shareholders   56,241 28,591 196.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PANACEA BIOTECH  BIOCON   FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 20, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS